Get the Stockscreener App
22.36
3.33%
0.72
After Hours:
22.36
Summit Therapeutics Inc stock is traded at $22.36, with a volume of 1.44M.
It is up +3.33% in the last 24 hours and up +24.99% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$21.64
Open:
$21.89
24h Volume:
1.44M
Relative Volume:
0.67
Market Cap:
$16.54B
Revenue:
$956.00K
Net Income/Loss:
$-196.68M
P/E Ratio:
-93.17
EPS:
-0.24
Net Cash Flow:
$-113.02M
1W Performance:
-9.29%
1M Performance:
+24.99%
6M Performance:
+109.17%
1Y Performance:
+493.89%
1-Day Range:
$21.55
$22.76
1-Week Range:
$21.55
$25.00
52-Week Range:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
22.36 | 16.54B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
(SMMT) Investment Report - Stock Traders Daily
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? - Yahoo Finance
Summit Therapeutics Inc. (NASDAQ:SMMT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? - Yahoo Finance
Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Purchased by Griffin Asset Management Inc. - MarketBeat
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond - The Motley Fool
Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio? - Benzinga
Assenagon Asset Management S.A. Makes New $229,000 Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Why Summit Therapeutics (SMMT) Is Skyrocketing Now - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.7%Time to Sell? - MarketBeat
Summit Therapeutics announces executive compensation changes - MSN
Summit Therapeutics retains Buy stock rating on clinical trial - MSN
Summit Therapeutics announces executive compensation changes By Investing.com - Investing.com Canada
Summit Therapeutics Grants Bonuses and Reports Strong Finances - TipRanks
Why Summit Therapeutics Stock Is Jumping Today - MSN
Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of targets - STAT
HC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics’ (SMMT) Buy Rating Reaffirmed at HC Wainwright - Defense World
Summit Therapeutics' (SMMT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Summit Therapeutics retains Buy stock rating on clinical trial By Investing.com - Investing.com Canada
12 Hot Stocks to Buy According to Analysts - Insider Monkey
Here’s Why Analysts Are Bullish on Summit Therapeutics Inc. (SMMT) - Yahoo Finance
Long Term Trading Analysis for (SMMT) - Stock Traders Daily
JPMorgan Chase & Co. Sells 1,101 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Is Summit Therapeutics (SMMT) the Best Russell 2000 Stock to Invest in According to Analysts? - MSN
Summit Therapeutics (SMMT) Stock Price, News & Analysis - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% HigherWhat's Next? - MarketBeat
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade) - Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.3%Here's What Happened - MarketBeat
Looking At Summit Therapeutics's Recent Unusual Options Activity - Benzinga
24,879 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Bought by SeaCrest Wealth Management LLC - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics (SMMT) Stock Surge Driven by Promising Drug Trials - GuruFocus.com
Why Summit Therapeutics Rocketed 584% in 2024 - MSN
Summit Therapeutics Highlights Success at Healthcare Conference - TipRanks
Summit Therapeutics (NASDAQ:SMMT) Stock Quotes, Forecast and News Summary - Benzinga
(SMMT) Technical Data - Stock Traders Daily
Summit Therapeutics (NASDAQ:SMMT) Shares Up 3.3%Should You Buy? - MarketBeat
Merck rival Summit draws new buy from Truist on deal prospects - Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Truist Financial - MarketBeat
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
SA Asks: Which biotechs are most likely to be acquired near-term? - Seeking Alpha
The Play On Summit Therapeutics (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $33.33 Consensus PT from Analysts - MarketBeat
Prediction: These 3 Healthcare Stocks Will Soar in 2025 - Yahoo Finance
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
5.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):